Landmark agreement between a leading virtual care company and a pharmaceutical manufacturer establishes an exclusive telehealth co-marketing arrangement with LifeMD for the XYOSTED self-pay program, l ...
Antares' (ATRS) Vibex QuickShot auto injector restored and maintained testosterone levels in a Phase II study of 29 patients. The testosterone-replacement market was worth $2.8B in sales in 2013.
Antares Pharma, Inc. has announced positive results from a multi-center phase 2 clinical study evaluating the pharmacokinetic profile of testosterone enanthate administered once-weekly by subcutaneous ...
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ:ATRS) today announced that a meeting was held with the U.S. Food and Drug Administration (FDA) to discuss a registration study for the VIBEX ...
Xyosted carries a Boxed Warning regarding blood pressure increases that may potentially increase the risk for major adverse cardiovascular events. The Food and Drug Administration (FDA) has approved ...
Antares Pharma, Inc. has reported positive results from a multi-centre phase II clinical study evaluating the pharmacokinetic profile of testosterone enanthate administered once-weekly by subcutaneous ...
The US Food and Drug Administration (FDA) has declined to approve a new drug application (NDA) for testosterone enanthate (Xyosted, Antares Pharma) in a proprietary autoinjector and has raised two ...
New Jersey based Antares has signed a deal with pharma giant Pfizer to develop an auto injector pen for an undisclosed Pfizer drug, adding 13% to its shares value on Nasdaq. The development of rescue ...
The Aidaptus ® disposable auto-injector platform, designed by Owen Mumford, will be jointly offered to global biopharma companies to support their drug development programs with engineering and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results